Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Aurinia Pharmaceuticals Inc. (T:AUP)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 1203-4464 Markham St
Tel: N/A
IR: See website
Key People
Peter S. Greenleaf
President, Chief Executive Officer, Director
Joe Miller
Chief Financial Officer
Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Matthew Donley
Executive Vice President, Operations and Strategy
Volker Knappertz
Executive Vice President - Research and Development
Scott Habig
Chief Commercial Officer
Michael R. Martin
Chief Business Officer
Business Overview
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. It also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.
Financial Overview
For the fiscal year ended 31 December 2022, Aurinia Pharmaceuticals Inc revenues increased from $45.6M to $134M. Net loss decreased 40% to $108.2M. Revenues reflect United States segment increase from $45.5M to $102.5M, Japan segment increase from $0K to $31.5M. Lower net loss reflects Research an decrease of 22% to $27.7M (expense), Interest income increase from $529K to $5.1M (income).
Employees: 300 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $1,178M as of Dec 31, 2022
Annual revenue (TTM): $134.03M as of Dec 31, 2022
EBITDA (TTM): -$108.76M as of Dec 31, 2022
Net annual income (TTM): -$108.18M as of Dec 31, 2022
Free cash flow (TTM): -$79.82M as of Dec 31, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 142,576,689 as of Feb 27, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization